StemCyte announced positive trial results showing that its HPC cord blood therapy was successful in treating patients with long COVID symptoms.1,3,4The company received FDA approval to initiate the phase 2a clinical trial. A total of 22 participants received the HPC cord blood treatment while 10 received a placebo. The Chalder Fatigue Questionnaire (CFQ-11) was used to measure fatigue severity.1,3Results showed significant improvement in overall fatigue symptoms, fatigue severity, and physical fatigue among long COVID patients treated with the HPC. StemCyte Announces FDA Clearance of Expanded Access Program for RegeneCyte® (HPC, Cord Blood) to Address Unmet Need in Long COVID. StemCyte Announces Successful Phase IIa Clinical Trial Results for HPC, Cord Blood in Treating Post-COVID Syndrome: 85% of Patients Experience Complete Relief from Fatigue Symptoms.